Global Artificial Insemination Market to Reach $2.5 Billion by 2027
Amid the COVID-19 crisis, the global market for Artificial Insemination estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 6.6% over the analysis period 2020-2027. Intrauterine Insemination, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intravaginal Insemination segment is readjusted to a revised 6.4% CAGR for the next 7-year period.
The U.S. Market is Estimated at $468.1 Million, While China is Forecast to Grow at 6.2% CAGR
The Artificial Insemination market in the U.S. is estimated at US$468.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$434.3 Million by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.2% and 5.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
Intratubal Insemination Segment to Record 6.1% CAGR
In the global Intratubal Insemination segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$60.7 Million in the year 2020 will reach a projected size of US$92.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$285.3 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 131-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.Competitors identified in this market include, among others,
- Genea Limited
- Hi-Tech Solutions
- Irvine Scientific
- KITAZATO CORPORATION
- Pride Angel Ltd.
- Rinovum Women’s Health, LLC.
- Rocket Medical PLC
- Vitrolife AB